Y, S., RW, K., AC, M., AH, B., & ED, B. (2014). Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. The European journal of health economics : HEPAC : health economics in prevention and care, 15(1), 69. https://doi.org/10.1007/s10198-013-0456-5
Chicago Style (17th ed.) CitationY, Samyshkin, Kotchie RW, Mörk AC, Briggs AH, and Bateman ED. "Cost-effectiveness of Roflumilast as an Add-on Treatment to Long-acting Bronchodilators in the Treatment of COPD Associated with Chronic Bronchitis in the United Kingdom." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care 15, no. 1 (2014): 69. https://doi.org/10.1007/s10198-013-0456-5.
MLA (9th ed.) CitationY, Samyshkin, et al. "Cost-effectiveness of Roflumilast as an Add-on Treatment to Long-acting Bronchodilators in the Treatment of COPD Associated with Chronic Bronchitis in the United Kingdom." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 15, no. 1, 2014, p. 69, https://doi.org/10.1007/s10198-013-0456-5.
